EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 157 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $312,779 | +95844.5% | 11,025 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $326 | -99.9% | 11,144 | +15.1% | 0.00% | 0.0% |
| Q3 2022 | $256,000 | -43.5% | 9,683 | -4.9% | 0.00% | -40.0% |
| Q2 2022 | $453,000 | -6.6% | 10,187 | +4.0% | 0.01% | 0.0% |
| Q1 2022 | $485,000 | +11.0% | 9,797 | +14.1% | 0.01% | 0.0% |
| Q4 2021 | $437,000 | -10.3% | 8,589 | -1.7% | 0.01% | -16.7% |
| Q3 2021 | $487,000 | +27.2% | 8,739 | -2.4% | 0.01% | +50.0% |
| Q2 2021 | $383,000 | +2.7% | 8,953 | +0.1% | 0.00% | -20.0% |
| Q1 2021 | $373,000 | -10.8% | 8,943 | -0.4% | 0.01% | -16.7% |
| Q4 2020 | $418,000 | +4.8% | 8,983 | -4.4% | 0.01% | -25.0% |
| Q3 2020 | $399,000 | +62.9% | 9,397 | +84.3% | 0.01% | +60.0% |
| Q2 2020 | $245,000 | +4.7% | 5,098 | +0.2% | 0.01% | 0.0% |
| Q1 2020 | $234,000 | +13.6% | 5,090 | +48.4% | 0.01% | +25.0% |
| Q4 2019 | $206,000 | – | 3,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
| Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
| Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
| Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
| Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
| U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
| GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
| Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |